Peptris secures ₹86 crore support to advance AI-discovered drug candidates
The ₹172-crore VIGOR programme will fund preclinical work and preparations for trials; the agreement does not establish that the medicines are safe or effective.
Bengaluru-based Peptris Technologies will receive ₹86 crore in support from the Technology Development Board to advance four AI-discovered drug candidates towards clinical development, the science and technology department announced on 12 October.
The support forms part of the ₹172-crore VIGOR project and will be provided through optionally convertible debt under the Research Development and Innovation Fund. It is a financing agreement for research and development, not an announcement of an approved medicine.
The three-year programme aims to move the candidates from Technology Readiness Level 4 to Level 6. Planned work includes preclinical validation, studies needed before applications to begin human trials, formulation development and preparation for clinical testing, subject to scientific and regulatory requirements.
The candidates target areas including neuromuscular disorders, oncology, alopecia, neuropathy and Duchenne muscular dystrophy. The announcement provides no human-trial efficacy results.
AI can help identify molecules worth investigating, but a computational prediction is only an early step. Experimental testing and the applicable approval processes remain essential before a candidate can become a treatment. For patients, the significance of today’s agreement is additional backing for that development pathway; it does not demonstrate safety, effectiveness or availability of the proposed therapies.